ArticleEuropean journal of epidemiology2026
Incidence and prevalence of autoimmune disease in the Swedish National Patient Register.
Article in European journal of epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Maternal body mass index in early pregnancy and offspring mortality up to early adulthood: A nationwide cohort study.PLoS medicine · 2026Article
- Clinical Management of Antirheumatic Drug Exposure During Therapeutic Plasma Exchange.Clinical reviews in allergy & immunology · 2026Review
- Autoimmune disease in offspring of mothers with metabolic dysfunction-associated steatotic liver disease (MASLD): a nationwide cohort study.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStandardized definitions of autoimmune disease (AD) are lacking. Therefore, we aim to propose a definition of AD for register-based research and estimate the burden of AD in Sweden as registered in the National Patient Register (NPR) from 1980 to 2023.
methodsLeveraging the NPR, we defined AD as having at least two relevant International Classification of Diseases (ICD) codes representing AD. These codes could either represent the same disease or two different diseases. Age-standardized and age-specific incidence rates (IRs) of AD were calculated, along with prevalence on December 31, 2023.
resultsFrom 1980 to 2023, the mean age-standardized IR of AD was 318 cases per 100,000 person-years (95% CI: 294–342). The IR decreased with the introduction of ICD-10 (1997), but then sharply increased in 2001 following the addition of specialized outpatient data to the NPR that year, likely reflecting improved case ascertainment rather than a sudden true rise in incidence. As of December 31, 2023, the prevalence of AD in Sweden was 6.6% overall, 7.9% in adults, and 1.5% in children.
conclusionsIn a nationwide study spanning more than 40 years, the IR of AD was 318 per 100,000 person-years but with substantial variation correlating to administrative changes in coding and content of the NPR. In 2023, the point prevalence of AD in Sweden was 1 in 15 individuals across all ages, 1 in 13 adults, and 1 in 67 children.
Indexed as
Identifiers
41721992What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.